Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 21, 2020

Astellas Pharma gets FDA fast track status for ASP036 to treat primary mitochondrial myopathies

Astellas Pharma has secured fast track status from the US Food and Drug Administration (FDA) to develop ASP0367/MA-0211 (ASP0367) as a potential treatment for primary mitochondrial myopathies (PMM).

The US FDA’s Center for Drug Evaluation and Research. (Credit: The U.S. Food and Drug Administration)